Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine

Oncology

Volumn 73, Issue 1-2, 2008, Pages 130-135

  Awar, Omar ^a   Duvic, Madeleine ^b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gemcitabine; Gemzar ; Lymphoma, cutaneous T cell; Lymphoma, large cell; Lymphoma, non Hodgkin; Mycosis fungoides

Indexed keywords

BEXAROTENE; CHLORMETHINE; CLARITHROMYCIN; CLOBETASOL; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; NAVELBINE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRIAMCINOLONE; VORINOSTAT;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DERMATITIS; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRON THERAPY; HEART ATRIUM FIBRILLATION; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; MALE; MALIGNANT TRANSFORMATION; MOLECULAR THERAPY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYCOBACTERIOSIS; MYCOSIS FUNGOIDES; NEUTROPENIA; PHOTOTHERAPY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MYCOSIS FUNGOIDES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 41549097425     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000121002     Document Type: Article

References (30)

1. Apisarnthanarax N, Talpur R, Duvic M: Treatment of cutaneous T-cell lymphoma: current status and future directions. Am J Clin Dermatol 2002;3:193-215.
2. Girardi M, Heald PW, Wilson LD: The Pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978-1988.
3. Lukes RJ, Collins RD: Immunologic characterization of human malignant lymphomas. Cancer 1974;34:1488.
4. Dmitrovsky E, Matthews MJ, Bunn PA, et al: Cytologic transformation in cutaneous T-cell lymphoma: a clinopathologic entity associated with poor prognosis. J Clin Oncol 1987;5:208.
5. Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins, RT: Transformation of cutaneous T-cell lymphoma to large-cell lymphoma: a clinicopathologic and immunologic study. Am J Pathol 1988;132:265.
6. Greer JP, Salhany KE, Cousar JB, et al: Clinical features associated with transformation of cerebriform T-cell lymphoma to a large-cell process. Hematol Oncol 1990;8:215.
7. Cerroni L, Rieger E, Hodl S, Kerl H: Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am J Surg Pathol 1992;16:543-552.
8. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R: Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998;92:1150-1159.
9. Vergier B, de Muret A, Beylot-Barry M, et al: Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000;95:2212-2218.
10. Shen S, Metz B, Ehrig T, Sinkre P, Hsu S: Capillaritis as a potential harbinger of cutaneous T-cell lymphoma. Dermatol Online J 2004;10:15.
11. Duvic M, Talpur R, Ni X, et al: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-39.
12. Dhillon N, Bakkannagari S, Ng C, Lim J, Duvic M, Kurzrock R: Cutaneous T-cell lymphoma: responses in phase I trial of combination therapy with liposomal doxorubicin, bortezomib, and gemcitabine (abstract 2466). Blood 2006;108:698a.
13. Kim EJ, Hess S, Richardson SK, et al: Immunopathogenesis and therapy of cutaneous T cell lymphoma: J Clin Invest 2005;115:798-812.
14. Bunn P.A, Hoffman S J, Norris D, et al: Systemic therapy of cutaneous T-Cell Lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994;121:592-602.
15. Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol Oncol Clin North Am 1995;9:1109-1116.
16. Foss, F: Mycosis fungoides and the Sezary syndrome. Curr Opin Oncol 2004;16:421-428.
17. Wollina U, Dummer R, Brockmeyer NH: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003;98:993-1001.
18. Foss FM: Combination therapy with purine nucleoside analogs. Oncology (Williston Park) 2000;14(suppl 2):31-35.
19. Foss FM, Ihde D, Breneman DL, et al: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 1992;10:1907-1913.
20. Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999;17:3117-3121.
21. Quaglino P, Fierro MT, Rossotto GL, Savoia P, Bernengo MG: Treatment of advanced mycosis fungoides/Sezary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol 2004;150:327-336.
22. Foss FM, Ihde DC, Linnoila IR, et al: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/ Sezary syndrome. J Clin Oncol 1994;12:2051-2059.
23. Olsen EA, Duvic M, Frankel A, et al: Pivotal phase III trial of two dose levels of denileukin for the treatment of cutaneous T cell lymphoma. J Clin Oncol 2001;19:376-388.
24. Anadolu RY, Birol A, Sanli H, Erdem C, Tursen U: Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients. Int J Dermatol 2005;44:559-565.
25. Nabhan C, Krett N, Gandhi V, Rosen S: Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001;13:514-521.
26. Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytatidine). Cancer Res 1990;50:4417-4422.
27. Zinzani PL, Baliva G, Magagnoli M, et al: Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18:2603-2606.
28. Duvic M, Rakhshandra T, Wen S, Kurzrock R, David CL, Apisarnthanarax N: Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006;7:51-58.
29. Sallah S, Wan JY, Nguyen NP: Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001;113:185-187.
30. Marchi E, Alinari L, Tani M, et al: Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005;104:2437-2441.